Inactive

Document Type: Combined Synopsis/Solicitation Solicitation Number: RFQ-NIH-NIAID-2023754 Description: This notice is a combined synopsis/solicitation for commercial items using Simplified Acquisition ... Document Type: Combined Synopsis/Solicitation Solicitation Number: RFQ-NIH-NIAID-2023754 Description: This notice is a combined synopsis/solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 “Streamlined Procedures for Evaluation and solicitation for commercial Items,” as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-NIH-NIAID-2023754 and the solicitation is issued as a Request for Quotes (RFQ). This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) FAC 2020-06 and effective 05/06/2020. The North American Industry Classification System (NAICS) code for this procurement is 325414 Biological Product (except diagnostic) Manufacturing business size standard of 500 employees. This requirement IS not SET-ASIDE for small business. Background and laboratory needs: The mission of the Vaccine Research Center (VRC) is to conduct research that facilitates the development of effective vaccines for human disease. ExpiFectamine™ 293 Reagent is a proprietary cationic lipid-based reagent for the transfection of nucleic acids into eukaryotic cells. To transfect high-density suspension Expi293F™cells, the lab scales the transfections up or down by proportionately adjusting the amounts of the reagents used. The Expifectamine transfection kit is unique in that it allows for high density growth and protein production, with the accompanied use of other 293Expi components such as specific cell lines. No other product yields the same results, we request this Brand Name for consistency in results. *This is a Brand-Name requirement for: QTY10 A14525 EXPIFECTAMINE TRANSFXN KIT 10L Kit *Please include your DUNS number *Include response to FAR 52.204-4 attachment and return with quote Place of Delivery: NIH/VRC, Bethesda, MD 20892 FOB: Destination Submission shall be received not later than 06/10/2020, 10:00 a.m. Eastern Standard Time The government intends to award a firm fixed price purchase order to the responsible contractor as a result of this RFQ that will include the terms and conditions set forth herein. The award will be based on the following; price, capability to meet the requirements, delivery and the best value to the government. The following FAR provisions apply to this acquisition: 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Dec 2019) FAR 52.212-1 Instructions to Offerors Commercial Items (March 2020) FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (March 2020) Offerors must complete annual representations and certifications on-line at http://www.sam.gov/ in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items (Please ensure 52.209-2 -- Prohibition on Contracting with Inverted Domestic Corporations--Representation. (Nov 2015) is updated in your SAM record) FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements – Representation (Jan 2017) The following FAR contract clauses apply to this acquisition: FAR 52-212-4 Contract Terms and Conditions Commercial Items (Oct 2018) FAR 52-212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (Oct 2019) *The applicable subparagraphs of FAR52.212-5 are included in the attachment to this posting. FAR 52.203-19 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements (Jan 2017) FAR 52.204-25 Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (Aug 2019) FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (Dec 2013) FAR 52.204-19 Incorporation by Reference of Representations and Certifications (Dec 2014) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (Dec 2015) By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov). Copies of the above-referenced provisions and clauses are available from http://www.acquisition.gov & http: //www.hhs.gov/regulation/index.html or, upon request, either by telephone or fax. Offers may be mailed, e-mailed or faxed to Lorena Waller, (E-Mail/ Wallelor@niaid.nih.gov 240-669-5099). Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f) (Oct 2018) All responsible sources may submit an offer that will be considered by this Agency. Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Lorena Waller @ Wallerlor@niaid.nih.gov -240-669-5099.